Stockreport

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF - PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p - Change from baseline in AHV was superior to placebo at Week 52 with a me [Read more]